Finlands Akademi
Finansieringsbeslut
 
Namn Satokari, Reetta
Organisation HY
Projektets titel Precision microbiota therapy for Clostridium difficile infection
Beslutnr 304490
Beslutsdatum 30.09.2016
Finansieringsperiod 01.10.2016 - 30.09.2018
Finansiering 298 814
WebFOCUS Report
Beskrivning av projektet
Our intestinal tract harbors a diverse microbial population –the microbiota – which contributes to our health in many ways e.g. by providing colonization resistance against pathogens. Clostridium difficile infection (CDI) is a diarrhea associated with loss of diversity and normal composition of microbiota due to antibiotic use. CDI has high rate of recurrency when treated traditionally by antibiotics, but fecal microbiota transplantation (FMT) from healthy donors is an effective cure for the disease. We have transferred improved protocols of FMT from research to clinical practice to make the therapy more readily available and cost-effective. Further, we are developing future therapy for CDI by isolating intestinal bacteria to be used for precision microbiota therapy. Among our bacterial isolates are many potentially new species. The aim is to help to treat CDI (5000 cases/year in Finland) and other diseases, which are associated with microbiota dysbiosis.